Yannick Hurni: Navigating Confounding in Target Trial Emulation Studies
Yannick Hurni, Clinical and Research Fellow in Gynecologic Surgery at Dexeus University Hospital, shared a post on LinkedIn:
“Target Trial Emulation: Conceptual Breakthrough or Methodological Comfort Blanket?
Target Trial Emulation (TTE) has quickly become one of the most fashionable frameworks in clinical epidemiology. And intellectually, it is powerful. It forces us to structure observational analyses as if we were designing an ideal RCT – eligibility criteria, treatment strategies, randomization, follow-up, analysis plan – all prespecified and transparent.
In theory, that rigor allows us to focus on what really matters: controlling for confounding.
And that is exactly where the real construction begins.
Once we move beyond true randomization, the credibility of a TTE depends entirely on how we emulate treatment assignment. That step is not cosmetic – it is the core of the causal claim.
In a recent TTE-based study published in Fertility and Sterility, treatment assignment was emulated using propensity score matching (PSM).
A legitimate choice – in principle. But everything hinges on:
- How covariates were selected (causal reasoning vs statistical significance?)
- Whether all plausible determinants of treatment allocation were included
- How matching was performed (caliper? replacement?)
- How balance was assessed (SMDs or p-values?)
This is the part that ‘mimics’ randomization. This is where we attempt to control for known confounders — since unknown ones are, by definition, uncontrollable.
If we cannot eliminate unknown confounding, then known confounders must be handled with maximal rigor.
My concern is that TTE risks becoming a methodological label rather than a methodological discipline. The structure is invoked, but the exchangeability construction – the most delicate step – is not always treated with the precision it demands.
TTE is not about giving observational data an RCT-shaped outline.
It is about engineering causal comparability.
So the question is not whether we are doing Target Trial Emulation.
The question is:
Are we truly building the target trial – or merely simulating its appearance?”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 13, 2026, 16:58Slavian Bumbu: A Low AMH Is Not an Infertility Diagnosis
-
Oct 13, 2026, 16:43Keshav Malhotra: No Embryologist or Laboratory Technique Can Guarantee Euploid Embryos
-
Oct 13, 2026, 16:37Tony Gordon: What Is the Most Successful Form of Fertility Treatment?
-
Oct 13, 2026, 16:29IVI RMA Global Introduces IVI Fertility
-
Oct 13, 2026, 16:12Devyanshi Dixit: PCOS May Be One Diagnosis, But Is It One Biological Disease?
-
Oct 13, 2026, 16:00Rajeev Agarwal: Age and Male Fertility, Through the PREPARE Method
-
Oct 13, 2026, 15:505 Years of the Patient Engagement Forum – HFEA
-
Oct 13, 2026, 15:41Cell-Free Fetal DNA Testing for Single-Gene Conditions – RCOG
-
Oct 13, 2026, 15:24Somil Singhal: Method for Enhancing Embryo Implantation Using Embryo Glue and Its Importance